

For Immediate Release**TSX Symbol: RVX****Resverlogix Corporate Update; New Science Board Member, Change of CFO,
and Live Web Cast Update**

CALGARY, AB, February 14, 2006 – Resverlogix Corp. (“Resverlogix”) (TSX: RVX), announced today that Dr. James K. Liao, Director of Vascular Research, Cardiovascular Division, Department of Medicine Brigham & Women's Hospital and Harvard Medical School Cambridge, Massachusetts, USA has joined the Scientific Advisory Board.

Dr. Liao has authored and participated in over 100 peer reviewed research articles in leading scientific publications and been a Editorial Board Member and Reviewer for leading Scientific Journals such as Circulation, American Journal of Cardiology, Pharmacology Review, Nature Medicine and the New England Journal of Medicine.

Dr. Liao has won numerous awards and Honors such as The American Heart Association Junior Fellowship in 1979; The Chancellor's Marshall Award, University of California 1981; The Cardiovascular Disease Research Prize (1st Place), American Heart Association 1998; and Three Distinction for Excellence in Teaching Awards, Harvard Medical School 1999, 2003, 2004. Dr. Liao has also served as scientific consultant to leading pharmaceutical organizations.

“We are very pleased to add a leading authority in vascular research such as Dr. Liao to our Scientific Advisory Board” stated Dr. Norman Wong, Chair of Resverlogix's Scientific Advisory Board. “Dr. Liao's knowledge and experience will provide complimentary medical expertise to our existing Resverlogix cardiovascular programs and help ensure our leadership position in Apo AI research,” added Dr. Wong.

In other news, Hiran Perera, Chief Financial Officer (CFO), is resigning his position, effective immediately, in order to execute an entrepreneurial venture with the support of his family. Hiran is available to Resverlogix in a consulting capacity for an interim period until a new CFO is hired. The Board of Directors thanks him for his service and wishes him well in his future endeavors.

In addition Resverlogix will be hosting a live Vcall web cast on Thursday February 23rd at 11:00am MST. Details of the web cast will include an update on ReVas™ developments relating to ongoing Licensing discussions and other corporate developments. The web cast link will be posted on the Resverlogix web site www.resverlogix.com prior to the event.

About Resverlogix Corp.

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology NEXVAS™, applies advanced medical research to develop therapies that increase high density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases (CVD). The Company's second CVD research program ReVas™ is dedicated to developing novel compounds for acute based drug therapy via a medical device. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Donald J. McCaffrey

President/CEO

Resverlogix Corp.

Phone: 403-254-9252 ext. 223

Fax: 403-256-8495

Email: don@resverlogix.com

Kenneth Lebioda

Vice President Business Development

Resverlogix Corp.

Phone: 403-254-9252 ext. 227

Fax: 403-256-8495

Email: ken@resverlogix.com